三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01530 三生制药

开市前 05-13 09:07:23

21.600

+0.000

0.00%

最高21.600	最低21.600	成交量0.00
今开21.600	昨收21.600	日振幅0.00%
总市值548.21亿	流通市值548.21亿	总股本25.38亿
成交额0.00	换手率0.00%	流通股本25.38亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01530","market":"HK","secType":"STK","nameCN":"三生制药","latestPrice":21.6,"timestamp":1778634191141,"preClose":21.6,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":2538000000,"shares":2538000000,"eps":3.954207547169811,"marketStatus":"开市前","change":0,"latestTime":"05-13 09:07:23","open":21.6,"high":21.6,"low":21.6,"amount":0,"amplitude":0,"askPrice":21.96,"askSize":2000,"bidPrice":21.6,"bidSize":500,"shortable":3,"etf":0,"ttmEps":3.954207547169811,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778635800000},"marketStatusCode":1,"adr":0,"listingDate":1433952000000,"exchange":"SEHK","adjPreClose":21.6,"dividendRate":0.011941,"openAndCloseTimeList":[[1778635800000,1778644800000],[1778648400000,1778659200000]],"volumeRatio":0,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01530","defaultTab":"news","newsList":[{"id":"2634102264","title":"中邮证券：维持三生制药(01530)“买入”评级 多项临床开展全球价值加速兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2634102264","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634102264?lang=zh_cn&edition=full","pubTime":"2026-05-12 13:46","pubTimestamp":1778564812,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中邮证券发布研报称，三生制药系国内医药领域的老牌企业，坐拥特比澳等多个现金牛品种，为研发创新输入动力。对外授权落地推动业绩高增，主业受政策扰动有所下滑公司与辉瑞就PD-1/VEGF双抗707达成的授权交易在报告期内确认了94.3亿元的许可收入，构成了总收入的53.3%。707授权辉瑞，多项临床开展全球价值加速兑现PD-1/VEGF双抗被视为下一代肿瘤免疫治疗的核心基石疗法，市场空间广阔。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01530","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633486142","title":"医美概念股普跌 三生制药(01530)领跌2.88% 机构指美容护理板块现处于“三低”状态","url":"https://stock-news.laohu8.com/highlight/detail?id=2633486142","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633486142?lang=zh_cn&edition=full","pubTime":"2026-05-08 13:24","pubTimestamp":1778217872,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医美概念股普跌，截至发稿，三生制药(01530)跌2.88%，卓珈控股(01827)跌2.22%，康哲药业(00867)跌2.06%，复锐医疗科技(01696)跌2.02%，四环医药(00460)跌1.61%。消息面上，华泰证券表示，美容护理板块现处于预期低/估值低/持仓低的“三低”状态，行业面/资金面/基本面等维度的边际改善均有可能带来积极变化。从财报情况来看，部分标的业绩改善迹象已现，复苏节奏和斜率略有差异。整体而言品牌商及医美上游厂商分化明显，代工厂逐步复苏，代运营商转型持续兑现。建议积极跟踪618/新品势能等催化剂，若个股有盈利预测上修潜力，戴维斯双击或可期待。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980934","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","IE00BMCWC346.EUR","01530","BK1585","SG9999015945.SGD","BK1593","BK1161","01696","IE00BYV24P56.USD","SG9999015952.SGD","SG9999015978.USD","LU2488822045.USD","HK0000165453.HKD","SG9999015986.USD","BK1600","IE00BVYPNQ40.USD","01827","BK1515","BK1100","BK1191","IE00BGHQDM52.EUR","IE00BVYPNP33.GBP","00867","00460","BK1215","SG9999004220.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633687104","title":"【券商聚焦】中国银河：医药行业进入复苏周期 CXO板块景气度较高","url":"https://stock-news.laohu8.com/highlight/detail?id=2633687104","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633687104?lang=zh_cn&edition=full","pubTime":"2026-05-08 09:00","pubTimestamp":1778202049,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中国银河证券表示，2025年医药行业上市公司营业收入增长0.4%，归母净利润增长3.9%，扣非净利润下降4.1%，2026年一季度营业收入增长1.1%，归母净利润下降3.2%，扣非净利润增长2.0%。2025全年医药行业收入端小幅微增，主要系医保控费趋严，仿制药、耗材等集采常态化开展导致行业承压。2026年一季度创新药产业链高景气度延续，收入增幅扩大、非经常性损益占比下降，行业整体经营盈利能力提升，进入复苏上行周期。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980878","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CXO","LU0417516738.SGD","LU2476274720.SGD","LU0640798160.USD","LU1303224171.USD","LU1961090484.USD","LU2778985437.USD","09926","LU1251922891.USD","02228","06821","LU0348735423.USD","01099","09688","LU0417516902.SGD","02268","BK1583","LU1719994722.HKD","BK0188","BK1207","BK1500","LU0561508036.HKD","LU1794554557.SGD","LU0588546209.SGD","LU0348766576.USD","06881","LU1969619763.USD","BK1141","03933","LU0417516571.SGD","LU0634319403.HKD","01530","02196","LU2328871848.SGD","BK0276","IE00BPRC5H50.USD","BK1197","06160","LU2488822045.USD","LU0348783233.USD","01789","601881","LU0348767384.USD","HK0000165453.HKD","02367","BK1588","LU0307460666.USD","BK1585","BK1593","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174317146","title":"异动解读 | 三生制药盘中大涨5.71%，Summit暴跌余波消退叠加生物科技板块集体反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1174317146","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174317146?lang=zh_cn&edition=full","pubTime":"2026-05-07 10:35","pubTimestamp":1778121316,"startTime":"0","endTime":"0","summary":"三生制药今日盘中大涨5.71%，引起了市场的广泛关注。消息面上，此前其合作伙伴Summit Therapeutics因财报不佳而暴跌，导致市场对双方核心管线AK112的预期下修，三生制药股价因此连续承压。当前，由该事件引发的恐慌情绪已得到充分释放。与此同时，生物科技板块今日整体呈现回暖态势，多只相关个股上涨，三生制药也随板块一同出现修复性反弹。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190557799","title":"三生制药4月股份变动：小幅增发34,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1190557799","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190557799?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:36","pubTimestamp":1778056585,"startTime":"0","endTime":"0","summary":"三生制药于2026年5月6日向香港联交所提交截至2026年4月30日止的股份变动月报表。报告显示，公司于4月期间因行使购股权新增发行34,000股普通股，发行后已发行股本从上月的2,538,005,412股上升至2,538,039,412股。本月因购股权行使所取得资金为259,080港元。月报显示，公司确认符合香港联交所对最低公众持股量的相关规定。公司表示会继续严格遵守香港联交所《上市规则》及相关法律规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150552598","title":"异动解读 | 多重利好催化，三生制药盘中大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=1150552598","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150552598?lang=zh_cn&edition=full","pubTime":"2026-04-30 10:41","pubTimestamp":1777516861,"startTime":"0","endTime":"0","summary":"三生制药今日盘中大涨5.04%，引起了市场的广泛关注。消息面上，多家券商发布研报力挺三生制药，华源证券维持\"买入\"评级，方正证券维持\"强烈推荐\"评级。公司基本面表现亮眼，营业收入和净利润均实现大幅增长，主要受益于与辉瑞就PD-1/VEGF双抗SSGJ-707达成授权交易，并确认了高额许可收入。此外，国家药监局近日授予公司艾曲泊帕乙醇胺干混悬剂新增适应症批件，同时公司即将在ASCO大会上发布SSGJ-707的两项核心临床数据，研发管线推进预期持续升温。南向资金近期亦持续加仓，且公司当前静态市盈率仅6.74倍，估值处于历史低位，共同构成了股价上涨的催化剂。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631577846","title":"港股异动 | 三生制药(01530)现涨超5% SSS68注射液三项适应症获中国IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2631577846","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631577846?lang=zh_cn&edition=full","pubTime":"2026-04-30 10:34","pubTimestamp":1777516454,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，三生制药现涨超5%，截至发稿，涨5.13%，报23.36港元，成交额3.02亿港元。值得一提的是，SSS68注射液是全球首个进入临床阶段的APRIL×BAFF双抗。值得注意的是，4月28日，三生制药自主研发的1类治疗用生物制品SSGJ-706注射液新药临床试验申请正式获得受理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","01530","BK4588","HK0000165453.HKD","BK1583","IND","VXUS","BK1593","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196236456","title":"三生制药2025年度核心业务与业绩表现显著提升，创新管线与全球布局持续深化","url":"https://stock-news.laohu8.com/highlight/detail?id=1196236456","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196236456?lang=zh_cn&edition=full","pubTime":"2026-04-29 20:29","pubTimestamp":1777465799,"startTime":"0","endTime":"0","summary":"资产负债方面，截至2025年12月31日，三生制药总资产达362.50亿元，较2024年增长约49.7%，流动资产与权益总额均大幅上升。展望后续，三生制药将持续发力新药研发与技术创新，关注肿瘤免疫、血液、免疫炎症及其他创新药领域，通过强化国际合作、持续推进合资与研发项目，加速全球化正在进行。整体来看，2025年对三生制药而言是业务与业绩双提速的重要里程碑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"三生制药2025年度核心业务与业绩表现显著提升，创新管线与全球布局持续深化","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630361468","title":"【券商聚焦】方正证券维持三生制药(01530)“强烈推荐”评级 指公司2025年业绩爆发","url":"https://stock-news.laohu8.com/highlight/detail?id=2630361468","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630361468?lang=zh_cn&edition=full","pubTime":"2026-04-27 17:12","pubTimestamp":1777281134,"startTime":"0","endTime":"0","summary":"金吾财讯 | 方正证券发布研报指，三生制药 预计将在2026年美国临床肿瘤学会大会发布两项核心临床数据：更新SSGJ-707单药治疗非小细胞肺癌的快速口头报告，以及SSGJ-707联合化疗一线治疗子宫内膜癌的壁报摘要。公司2025年业绩爆发，实现营业收入176.96亿元，同比增长94.3%，主要源于与辉瑞就PD-1/VEGF双抗707达成授权交易确认许可收入94.26亿元，占比总收入的53.2%。净利润达84.82亿元，同比增幅305.78%。生物药销售降至80.06亿元，同比下降10.3%，主要受集采降价影响。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980016","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["601901","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629819536","title":"【券商聚焦】招商证券维持三生制药(01530)“强烈推荐”评级 指公司价值显著低估","url":"https://stock-news.laohu8.com/highlight/detail?id=2629819536","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629819536?lang=zh_cn&edition=full","pubTime":"2026-04-24 16:37","pubTimestamp":1777019869,"startTime":"0","endTime":"0","summary":"剔除授权收入后，核心生物药品销售额因集采和医保政策影响同比下降10.3%至80.1亿元。2025年公司与辉瑞达成重磅授权协议，是公司价值重估的核心催化剂。2025年辉瑞完成交割后公布7项临床方案，2026年新增多项方案，目前已登记9项临床试验。招商证券维持“强烈推荐”评级。当前公司市值未体现707分子作为下一代IO基石药物的潜力，海外合作伙伴辉瑞高效推进临床试验，707分子价值有望持续扩大、兑现。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979891","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530","06099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629023400","title":"港股异动 | 创新药概念全线走低 油价上涨压制降息空间 市场关注创新药投融资前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2629023400","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629023400?lang=zh_cn&edition=full","pubTime":"2026-04-23 13:59","pubTimestamp":1776923941,"startTime":"0","endTime":"0","summary":"消息面上，地缘局势不确定性持续存在，油价上涨推升通胀预期压制降息空间。招商银行研究院发布报告称，2025年，受到全球地缘政治压力以及美联储降息节奏的影响，全球创新药融资同比下降7.1%，但Q3的融资额已恢复8%的正增长。2026年如果美伊战争影响逐渐消除，美联储仍能持续降息，创新药投融资有望持续恢复。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4570","LU2097828805.USD","06978","LU2097828474.EUR","USE","LU2328871848.SGD","OILU","BK4585","BNO","LU1969619763.USD","PXJ","BK1593","LU2097828714.EUR","DRLL","USOI","LU2097828557.USD","DBC","03692","IXC","OIH","BK1574","IEO","VXUS","UGA","DBO","HK0000165453.HKD","GUSH","01801","DIG","DUG","LU2097828631.EUR","LU2242644610.SGD","159992","OILT","BK1583","LU0455707207.USD","BK1191","BK1161","09995","LU2488822045.USD","BK1589","DRIP","LU0502904849.HKD","DBE","OILK","VDE","01530","ERX","BWET","USL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628719049","title":"招银国际：医疗板块风险偏好有温和的修复 推荐翰森制药(03692)等6股","url":"https://stock-news.laohu8.com/highlight/detail?id=2628719049","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628719049?lang=zh_cn&edition=full","pubTime":"2026-04-20 11:36","pubTimestamp":1776656176,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，MSCI中国医疗指数2026年初至今累计上涨12.3%，跑赢MSCI中国指数13.6%。近期在中国政府工作报告将生物医学列为新兴支柱产业的政策催化下，板块风险偏好有温和的修复。同时，AI制药技术突破与中国创新药出海 BD 的爆发形成双重共振，该行预期产业基本面加速向好。招商国际给予该6只股份“买入”的投资评级，目标价分别为46.41港元、113.86港元、34.87港元、10.34港元、82港元及35.46美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430519.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","01167","01530","BK1161","LU2488822045.USD","LU2328871848.SGD","LU2097828714.EUR","02268","LU2242644610.SGD","LU0455707207.USD","LU1969619763.USD","BK1593","LU2097828474.EUR","LU2097828805.USD","01801","LU2097828631.EUR","LU2097828557.USD","159891","LU0502904849.HKD","BK1191","BK1574","03692","BK1589","BK1141","HK0000165453.HKD","SG9999014674.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121984026","title":"异动解读 | 三生制药盘中大涨5.30%，新药获批临床及低估值成催化剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1121984026","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121984026?lang=zh_cn&edition=full","pubTime":"2026-04-17 09:33","pubTimestamp":1776389624,"startTime":"0","endTime":"0","summary":"三生制药今日盘中股价大幅上涨5.30%，引起了市场的广泛关注。消息面上，公司旗下在研新药SSGJ-707（PF-08634404）近日获得国家药品监督管理局药品审评中心批准两项重磅适应症的临床试验，分别用于联合化疗一线治疗转化型小细胞肺癌，以及单药或联合治疗局部晚期或转移性肾细胞癌。这一研发进展被视为公司创新管线的重要突破，增强了市场对其未来增长潜力的信心。此外，投行摩根士丹利维持了对该公司的“增持”评级，并给出目标价。同时，公司当前估值水平较低，静态市盈率约6.74倍，叠加创新药物的持续推进，共同推动了市场做多情绪。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627405785","title":"港股三生制药午后一度涨超9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627405785","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627405785?lang=zh_cn&edition=full","pubTime":"2026-04-15 14:41","pubTimestamp":1776235315,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月15日，三生制药(01530.HK)午后一度涨超9%，截至发稿涨7.2%，报24.7港元，成交额13.03亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153705816241.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705816241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","HK0000165453.HKD","BK1161","BK4585","BK1593","01530","VXUS","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627540590","title":"港股异动 | 三生制药(01530)午后涨超9% SSGJ-707国内获批肺癌、肾癌临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2627540590","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627540590?lang=zh_cn&edition=full","pubTime":"2026-04-15 14:35","pubTimestamp":1776234920,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，三生制药午后涨超9%，截至发稿，涨7.2%，报24.7港元，成交额13.03亿港元。消息面上，4月7日，CDE官网显示，辉瑞申报的1类新药PF-08634404正式获批两项重磅适应症临床：联合化疗一线治疗转化型小细胞肺癌，以及单药/联合治疗局部晚期或转移性肾细胞癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK4588","HK0000165453.HKD","BK4585","01530","BK1593","BK1161","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627496144","title":"大摩：降三生制药(01530)目标价至34港元 评级“增持”","url":"https://stock-news.laohu8.com/highlight/detail?id=2627496144","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627496144?lang=zh_cn&edition=full","pubTime":"2026-04-14 11:26","pubTimestamp":1776137216,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，大摩发布研报称，纳入三生制药(01530)2025年业绩报，下调三生制药核心商业化产品TPIAO销售预测及里程碑付款，主要受美元兑人民币贬值影响，将公司2026至2028年收入预测分别下调5%、7%及6%。亦根据最新趋势调低产品毛利率，并调整营运开支比率。将同期每股盈利预测分别下调8.3%、14.5%及12.4%。目标价由38港元降至34港元。评级增持。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428134.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174752895","title":"一周港股牛熊榜 | 迅策周涨56%、滴普科技飙52%；稳定币牌照催化，国泰君安国际升31%","url":"https://stock-news.laohu8.com/highlight/detail?id=1174752895","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174752895?lang=zh_cn&edition=full","pubTime":"2026-04-10 16:47","pubTimestamp":1775810821,"startTime":"0","endTime":"0","summary":"近期港股市场整体活跃，多只中小市值个股创阶段新高，而怡俊集团控股亦成为资金关注对象之一。TCL电子本周升幅29.85%消息面上，公司近期发布 2025年全年业绩，业绩表现强劲，成为股价上涨的重要催化。业绩公布后，市场反应积极，股价一度 大涨超过10%。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"324431b18d184842b2237adf08e51534","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03033","02565","01384","01788","03668","03625","HSI","01530","02656","03317","HSTECH","02889","09903"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2626677051","title":"财报之后，南向资金能否撑起三生制药(01530)的股价反弹？","url":"https://stock-news.laohu8.com/highlight/detail?id=2626677051","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626677051?lang=zh_cn&edition=full","pubTime":"2026-04-10 15:57","pubTimestamp":1775807844,"startTime":"0","endTime":"0","summary":"去年5月20日，三生制药与辉瑞达成了一项交易总额最高逾60亿美元的大型BD交易，并凭借其中高达14亿美元的首付款刷新了国产创新药出海首付款金额的纪录。授权交易达成后，辉瑞还将按30日成交量加权平均价认购了三生制药1亿美元普通股。而近日，这项大型BD交易带来的正面影响映射在了三生制药的年报中。在后续港股创新药牛市带动下，三生制药股价2025年度涨幅高达314.75%，若以年度高点36.8港元计算，公司股价年内最高涨幅则达到了531.22%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625946383","title":"三生制药发声明：与三生（中国）和宁波三生不存在任何关联","url":"https://stock-news.laohu8.com/highlight/detail?id=2625946383","media":"华夏时报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625946383?lang=zh_cn&edition=full","pubTime":"2026-04-08 19:53","pubTimestamp":1775649180,"startTime":"0","endTime":"0","summary":"在医药行业品牌集中度持续提升、市场主体日益多元的当下，“同名”或“近似名”引发的主体混淆问题逐渐成为行业关注的焦点。近日，三生制药发布官方声明，明确其与“三生（中国）健康产业有限公司”“宁波三生生物科技股份有限公司”不存在任何关联关系，此举既是对市场问询的正面回应，也折射出医药企业在品牌保护与市场区隔上的行业共性需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604083698247875.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604083698247875.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000165453.HKD","BK1593","01530","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179219096","title":"异动解读 | 三生制药盘中大跌6.46%，机构下调盈利预测施压","url":"https://stock-news.laohu8.com/highlight/detail?id=1179219096","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179219096?lang=zh_cn&edition=full","pubTime":"2026-04-08 13:50","pubTimestamp":1775627451,"startTime":"0","endTime":"0","summary":"三生制药今日盘中股价出现大幅下跌，跌幅达6.46%，市场表现引人关注。消息面上，国信证券发布报告指出，三生制药的国内药品销售业务存在一定压力。基于此，该机构小幅下调了公司2026-2027年的盈利预测，并新增了2028年的预测。具体来看，预计2026年至2028年公司归母净利润分别为24.5亿元、26.6亿元和27.9亿元，其中2026年预测较此前值28.8亿元有所下调。这一盈利预期的下调，被认为是导致股价承压下行的重要原因。报告同时也提到，公司的在研药物“707”快速开启了全球3期多中心临床，未来有望成为重磅产品，并因此维持了对公司“优于大市”的评级。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01530"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.3sbio.com","stockEarnings":[{"period":"1week","weight":-0.0314},{"period":"1month","weight":-0.0592},{"period":"3month","weight":-0.1045},{"period":"6month","weight":-0.3606},{"period":"1year","weight":0.9405},{"period":"ytd","weight":-0.1067}],"compareEarnings":[{"period":"1week","weight":0.0173},{"period":"1month","weight":0.0175},{"period":"3month","weight":-0.0337},{"period":"6month","weight":-0.0268},{"period":"1year","weight":0.1188},{"period":"ytd","weight":0.028}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"3SBio Inc是一家主要从事生物制药产品的开发、生产、市场推广及销售的投资控股公司。该公司的主要产品包括特比澳、益比奥、益赛普、赛普汀等生物药物以及蔓迪、丽美治等小分子药物。该公司还从事为客户提供多种生物药的研发生产以及治疗技术平台服务的合同开发与生产运营（CDMO）业务。该公司的产品主要应用于血小板减少症（CIT）、慢性肾病（CKD）引起的贫血症、治疗化疗引起的贫血症（CIA）、强直性嵴柱炎（AS）及银屑病等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.00666},{"month":2,"riseRate":0.454545,"avgChangeRate":0.00178},{"month":3,"riseRate":0.818182,"avgChangeRate":0.113214},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.011081},{"month":5,"riseRate":0.636364,"avgChangeRate":0.093133},{"month":6,"riseRate":0.8,"avgChangeRate":0.036581},{"month":7,"riseRate":0.090909,"avgChangeRate":-0.038254},{"month":8,"riseRate":0.363636,"avgChangeRate":-0.014022},{"month":9,"riseRate":0.636364,"avgChangeRate":0.027455},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.018307},{"month":11,"riseRate":0.727273,"avgChangeRate":0.059913},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.045323}],"exchange":"SEHK","name":"三生制药","nameEN":"3SBIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三生制药,01530,三生制药股票,三生制药股票老虎,三生制药股票老虎国际,三生制药行情,三生制药股票行情,三生制药股价,三生制药股市,三生制药股票价格,三生制药股票交易,三生制药股票购买,三生制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三生制药(01530)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三生制药(01530)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}